000285371 001__ 285371
000285371 005__ 20240718152449.0
000285371 0247_ $$2doi$$a10.1016/j.euo.2023.10.013
000285371 0247_ $$2pmid$$apmid:37949729
000285371 0247_ $$2altmetric$$aaltmetric:156312415
000285371 037__ $$aDKFZ-2023-02340
000285371 041__ $$aEnglish
000285371 082__ $$a610
000285371 1001_ $$aMoen, Christian A$$b0
000285371 245__ $$aPenile Cancers Attributed to Human Papillomavirus Are Associated with Improved Survival for Node-positive Patients. Findings from a Norwegian Cohort Study Spanning 50 Years.
000285371 260__ $$aAmsterdam$$bElsevier$$c2024
000285371 3367_ $$2DRIVER$$aarticle
000285371 3367_ $$2DataCite$$aOutput Types/Journal article
000285371 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721309044_2266
000285371 3367_ $$2BibTeX$$aARTICLE
000285371 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285371 3367_ $$00$$2EndNote$$aJournal Article
000285371 500__ $$a2024 Aug;7(4):778-785
000285371 520__ $$aHuman papillomavirus (HPV) infection is a risk factor for the development of penile squamous cell carcinoma (PSCC). It remains inconclusive whether HPV-related PSCC has a different prognosis from non-HPV-related PSCC.To investigate the relationship between HPV status and survival as well as temporal changes in the proportion of HPV-related PSCC.A retrospective cohort of 277 patients treated in Norway between 1973 and 2022 was investigated for HPV DNA in tumor tissue. Clinicopathological variables and disease course were registered.Kaplan-Meier curves and Cox regression were used to investigate the determinants of cancer-specific survival (CSS). The chi-square test for trend in proportions enabled investigation of temporal changes in the HPV-related proportion of PSCC patients treated in Western Norway (n = 211).HPV DNA was detected in tumor tissue from 131 (47%) patients. Stratified by HPV status, 5-yr CSS did not differ between groups (p = 0.37). When investigating only node-positive patients, however, presence of HPV DNA was an independent predictor of better survival in multivariable Cox regression after adjustment for age, nodal stage, and adjuvant therapy (hazard ratio 0.54, 95% confidence interval: [0.30-0.99], p = 0.04). In cases from Western Norway, an increasing proportion of HPV-related cases over time was found (p = 0.01). The main limitation is the retrospective study design.HPV DNA in tumor tissue was associated with significantly better CSS for node-positive patients. The proportion of HPV DNA-positive PSCC has increased significantly in Western Norway over the past 50 yr.We investigated the impact of human papillomavirus (HPV) on the survival of penile cancer patients treated over a 50-yr period in Norway. We found that for patients with lymph node metastasis, survival was better for HPV-related cases. We also found that the proportion of cases due to HPV has increased in Western Norway.
000285371 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000285371 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285371 650_7 $$2Other$$aCancer-specific survival
000285371 650_7 $$2Other$$aHuman papillomavirus
000285371 650_7 $$2Other$$aNet survival
000285371 650_7 $$2Other$$aPenile cancer
000285371 650_7 $$2Other$$aPenile squamous cell carcinoma
000285371 7001_ $$aFalkenthal, Thea E$$b1
000285371 7001_ $$aThorkelsen, Tor K$$b2
000285371 7001_ $$aHopland, Andreas$$b3
000285371 7001_ $$aRio, Oline E$$b4
000285371 7001_ $$aHonoré, Alfred$$b5
000285371 7001_ $$aJuliebø-Jones, Patrick$$b6
000285371 7001_ $$aDongre, Harsh N$$b7
000285371 7001_ $$aCostea, Daniela E$$b8
000285371 7001_ $$aBostad, Leif$$b9
000285371 7001_ $$aBrennan, Paul$$b10
000285371 7001_ $$aJohansson, Mattias$$b11
000285371 7001_ $$aFerreiro-Iglesias, Aida$$b12
000285371 7001_ $$0P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aBrenner, Nicole$$b13$$udkfz
000285371 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b14$$udkfz
000285371 7001_ $$aNygård, Mari$$b15
000285371 7001_ $$aBeisland, Christian$$b16
000285371 773__ $$0PERI:(DE-600)2945338-0$$a10.1016/j.euo.2023.10.013$$gp. S258893112300233X$$n4$$p778-785$$tEuropean urology oncology$$v7$$x2588-9311$$y2024
000285371 909CO $$ooai:inrepo02.dkfz.de:285371$$pVDB
000285371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000285371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000285371 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000285371 9141_ $$y2023
000285371 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL ONCOL : 2022$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000285371 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR UROL ONCOL : 2022$$d2023-08-25
000285371 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000285371 980__ $$ajournal
000285371 980__ $$aVDB
000285371 980__ $$aI:(DE-He78)F020-20160331
000285371 980__ $$aUNRESTRICTED